OUR HISTORY
OUR SCIENCE
At Manhattan Bio, we are relentlessly learning how to attack fundamental vulnerabilities of cancer cells through antibody-drug conjugates (ADCs). Our innovative platforms enable precise targeting and delivery of therapeutic payloads to cancer cells while sparing healthy tissues. Our science combines cutting-edge antibody engineering with breakthrough advances in linker chemistry and payload design. We are pioneering next-generation ADCs to overcome critical limitations in current approaches – particularly toxicity and cancer resistance – through innovations in linker chemistry and strategic payload selection. The company leverages sophisticated antibody-based formats to create unique mix-and-match biologics capable of distributing selected protein- or chemical payloads to disease sites within the human body.
Our ADC program builds on the groundbreaking work of our esteemed scientists Dr. Nathan Tumey and Dr. Dhaval Shah, consecutive recipients of the World ADC Awards’ Outstanding Academic Investigator Award (2023 and 2022, respectively). As world-leading experts in medicinal chemistry, bioconjugation, linker-payload optimization and pharmacokinetics and pharmacodynamics (PK/PD) modeling and simulation, their unparalleled expertise drives the advancement of our ADC pipeline. Our scientific foundation is strengthened by the insights Dr. Ronald T. Raines, a renowned protein chemist and advisor whose pioneering work in protein chemistry and cellular penetration mechanisms informs our ADC design strategies. Dr. Raines, recipient of the Murray Goodman Memorial Prize and the Royal Society of Chemistry’s Khorana Prize, brings invaluable expertise in protein structure and cellular entry that enhances our ADC development capabilities. Today, empowered by advances across chemistry, protein engineering, and cancer biology, we are at the forefront of engineering custom-designed ADCs with potentially transformative applications in cancer treatment
PARTNERSHIPS
Manhattan BioSolutions, Inc. has built its foundation through collaborations with academic researchers, leading medical centers, and strategic partners, with a specific focus on advancing new classes of targeted biologic agents in areas of major unmet medical need. Manhattan Bio’ research efforts are augmented by scientific partnerships with the the National Cancer Institute (NCI), The Pediatric Preclinical In Vivo Testing Consortium (PIVOT), The Massachusetts Institute of Technology (MIT), The University of British Columbia, Stony Brook University, Binghamton University, University at Buffalo University, EVQLV and the INSERM. Through these collaborations, we aim to further explore and enhance the potential of targeted therapies to address orphan diseases and improve patient outcomes.
